Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer
LUND, Sweden, Dec. 9, 2024 /PRNewswire/ — Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).
One key finding was Immunovia’s next-generation test was equally accurate in detecting both stage 1 and stage 2 pancreatic cancers, reinforcing its strength as an early detection test. It is still very early, but provides hope for early detection of pancreatic cancer in a control sample of participants who have a family history or are genetically exposed. Click here to read more.